Skip to main content
Log in

p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells

  • Original Paper
  • Published:
Journal of Biomedical Science

Abstract

This study examined the effects of p53 gene status on DNA damage-induced cell death and chemosensitivity to various chemotherapeutic agents in non-small cell lung cancer (NSCLC) cells. A mutant p53 gene was introduced into cells carrying the wild-type p53 gene and also vice versa to introduce the wild-type p53 gene into cells carrying the mutant p53 gene. Chemosensitivity and DNA damage-induced apoptosis in these cells were then examined. This study included five cell lines, NCI-H1437, NCI-H727, NCI-H441 and NCI-H1299 which carry a mutant p53 gene and NCI-H460 which carries a wild-type p53 gene. Mutant p53-carrying cells were transfected with the wild-type p53 gene, while mutant p53 genes were introduced into NCI-H460 cells. These p53 genes were individually mutated at amino acid residues 143, 175, 248 and 273. The representative cell line NCI-H1437 cells transfected with wild-type p53 gene (H1437/wtp53) showed a dramatic increase in susceptibility to three anticancer agents (7-fold to cisplatin, 21-fold to etoposide, and 20-fold to camptothecin) compared to untransfected or neotransfected H1437 cells. An increase in chemosensitivity was also observed in wild-type p53 transfectants of H727, H441, H1299 cells. The results of chemosensitivity were consistent with the observations on apoptotic cell death. H1437/wtp53 cells, but not H1437 parental cells, exhibited a characteristic feature of apoptotic cell death that generated oligonucleosomal-sized DNA fragments. In contrast, loss of chemosensitivity and lack of p53-mediated DNA degradation in response to anticancer agents were observed in H460 cells transfected with mutant p53. These observations suggest that the increase in chemosensitivity was attributable to wild-type p53 mediation of the process of apoptosis. In addition, our results also suggest that p53 gene status modulates the extent of chemosensitivity and the induction of apoptosis by different anticancer agents in NSCLC cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bissonnette RP, Echeverri F, Mahboubi A, Green DR. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 359:552–554;1992.

    Google Scholar 

  2. Chen J-Y, Funk WD, Wright WE, Shay JW, Minna JD. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene 8:2159–2166;1993.

    Google Scholar 

  3. Chiba I, Takahashi T, Nau MM, D'Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H, Reissman PT, Slamon DJ, Holmes EC, Minna JD. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5:1603–1610;1990.

    Google Scholar 

  4. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849–852;1993.

    Google Scholar 

  5. Doyle LA. Mechanisms of drug resistance in human lung cancer cells. Semin Oncol 20:326–337;1993.

    Google Scholar 

  6. Fisher DE. Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539–542;1994.

    Google Scholar 

  7. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W-W, Owen-Schaub LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287–2291;1994.

    Google Scholar 

  8. Guillouf C, Rosselli F, Krishnaraju K, Moustacchi E, Hoffman B, Liebermann DA. p53 involvement in control of G2 exit of the cell cycle: Role in DNA damage-induced apoptosis. Oncogene 10:2263–2270;1995.

    Google Scholar 

  9. Heimdal K, Lothe RA, Lystad S, Holm R, Fossa SD, Borresen AL. No germline TP53 mutations detected in familial and bilateral testicular cancer. Genes Chromosomes Cancer 6:92–97;1993.

    Google Scholar 

  10. Jonveaux P, Berger R. Infrequent mutations in the p53 gene in primary human T-cell acute lymphoblastic leukemia. Leukemia 5:839–840;1991.

    Google Scholar 

  11. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51:6304–6311;1991.

    Google Scholar 

  12. Kishimoto Y, Murakami Y, Shiraishi M, Hayashi K, Sekiya T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinoma of the lung. Cancer Res 52:4799–4804;1992.

    Google Scholar 

  13. Kuerbitz SJ, Plunkett BS, Walsh WV, Kanstan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491–7495;1992.

    Google Scholar 

  14. Lai SL, Goldstein LJ, Gottesman MM, Pastan I, Tsai CM, Johnson BE, Mulshine JL, Ihde DC, Kayser K, Gazdar AF. MDR1 gene expression in lung cancer. J Natl Cancer Inst 81:1144–1150;1989.

    Google Scholar 

  15. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847–849;1993.

    Google Scholar 

  16. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957–967;1993.

    Google Scholar 

  17. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 266:807–810;1994.

    Google Scholar 

  18. Miller CW, Kimon K, Aslo A, Kok K, Yokota J, Buys CHCM, Terada M, Koeffler HP. p53 mutations in human lung tumors. Cancer Res 52:1695–1698;1992.

    Google Scholar 

  19. Miller CW, Chumakov A, Said J, Chen DL, Aslo A, Koeffler HP. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription. Oncogene 8:1815–1824;1993.

    Google Scholar 

  20. Milner J, Medcalf EA. Construction of activated mutant p53 with wild-type drives the wild-type p53 protein into the mutant conformation. Cell 65:765–774;1991.

    Google Scholar 

  21. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, Oie HK, Linnoila RI, Mulshine JL, Minna JD, Gazdar AF. p53 gene mutations in non-small cell lunger cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171–180;1992.

    Google Scholar 

  22. Mitsudomi T, Oyama T, Kusano T, Osaki T, Nakanishi R, Shirakusa T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J Natl Cancer Inst 85:2018–2023;1993.

    Google Scholar 

  23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxic assays. J Immunol Methods 65:55–63;1983.

    Google Scholar 

  24. Nelson WG, Kastan MB. DNA strand breads: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815–1823;1994.

    Google Scholar 

  25. O'Connor PM, Jackman J, Bae I, Myers T, Fan S, Scudiero D, Monks A, Sausville E, Weinstein J, Friend S, Fornace AJJ, Kohn KW. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285–4300;1997.

    Google Scholar 

  26. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828–4831;1992.

    Google Scholar 

  27. Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 89:4495–4499;1992.

    Google Scholar 

  28. Skladanowski A, Larsen AK. Expression of wild-type p53 increases etoposide cytotoxicity in M1 myeloid leukemia cells by facilitated G2 to M transition: Implications for gene therapy. Cancer Res 57:818–823;1997.

    Google Scholar 

  29. Spitz FR, Nguyen D, Skibber JM, Meyn RE, Cristiano RJ, Roth JA. Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation. Clin Cancer Res 2:1665–1671;1996.

    Google Scholar 

  30. Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD. p53: A frequent target for genetic abnormalities in lung cancer. Science 246:491–494;1989.

    Google Scholar 

  31. Tsai C-M, Chang K-T, Perng R-P, Mitsudomi T, Chen M-H, Kadoyama C, Gazdar AF. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutation. N Natl Cancer Inst 85:897–901;1993.

    Google Scholar 

  32. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 70:523–526;1992.

    Google Scholar 

  33. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352:345–347;1991.

    Google Scholar 

  34. Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB. Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 8:2555–2559;1993.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lai, SL., Perng, RP. & Hwang, J. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J Biomed Sci 7, 64–70 (2000). https://doi.org/10.1007/BF02255920

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02255920

Key Words

Navigation